Navigation Links
Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation
Date:5/20/2008

- Data from two clinical trials presented at International ATS Conference -

NAPA, Calif., May 20 /PRNewswire/ -- Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist(TM) Inhalation Solution (formoterol fumarate inhalation solution; FFIS) has a pharmacodynamic and pharmacokinetic profile that is comparable to the dry powder inhaler (DPI) formulation of formoterol fumarate, Foradil(R) Aerolizer(R) 12mcg (FA).

Perforomist(TM) (formoterol fumarate) Inhalation Solution, the only FDA- approved nebulized formoterol fumarate, was approved in 2007 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

The first of the two studies presented, "Dose-Ranging Study in COPD Patients Comparing Pharmacodynamics of Formoterol Fumarate Delivered by Nebulization and DPI," showed that 20mcg of FFIS (Perforomist(TM) Inhalation Solution) delivered by nebulization provides bronchodilation comparable to DPI delivery.

The second study; "A Pharmacokinetic Study in COPD Patients Comparing Formoterol Fumarate Delivered by Nebulization and DPI," showed comparability in linear kinetics and excreted drug levels between formoterol fumarate administered by nebulization and DPI. Transient and dose-related effects on serum potassium, serum glucose and vital signs were observed and found to be comparable between the two formulations.

Dr. Nicholas J. Gross, MD, PhD, Hines VA Hospital, Stricht Loyola School of Medicine and lead clinical investigator in the first study, commented, "The results of both of these studies provide additional evidence of the clinical benefit of Perforomist(TM) Inhalation Solution as a valuable treatment option for patients with COPD. Nebulization is an alternative way to deliver medication to the lungs and since many patients may have diffic
'/>"/>

SOURCE Dey L.P.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
2. New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
3. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
4. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
5. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
6. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
7. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
8. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
9. Clarient to Commercialize Novel Breast Cancer Profile
10. Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400
11. Derma Sciences MEDIHONEY(TM) Profiled in Several Television News Health Reports

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...he New York investment bank KTA Capital,s client N...AU$6.7 mil convertible note private placement with...ent was arranged by KTA Capital as Neuren,s exclus... New York (PRWEB) November 23, 2009 -- Th..., LLC ("KTA Capital") has announced that...
(Date:11/24/2009)...ov. 24 Sigma-Aldrich Cor...e NASDAQ OMX conference on Tuesday, December 1st a...d parties may listen via live audio broadcast over...ig m a a ldrich.com/ . Users can click the "... Sigma-Aldrich: Sigma-Aldrich is a leading Life ...
(Date:11/24/2009)...Calif., Nov. 24 Neuroges...any focused on developing and commercializing nove...Anthony DiTonno, President and Chief Executive Off...iper Jaffray Health Care Conference, to be held De...ew York, New York. ,, Mr. DiTonno and Stephen ...
(Date:11/24/2009)...fficacy endpoint has been met for patients with ad..., QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/...) (the "Company"), a global biopharmaceutical comp...ay announced positive efficacy data from a Phase 2...te, AEZS-108 (formerly AN-152), in patients with a...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...stics,Inc. (OTC Bulletin Board: BOVD) ("Boveran") ...t ("LOI") to acquire majority interest in Sophora,...ology lab ("Sophora")., Pursuant to the LOI, Dr. ...he Company,s Chief Pathologist and Director of Lab... lab services., Sophora is Boveran,s first planne...
...are Simplifies Medicare - For Free, MAYNARD, Mass...atest release of their PlanPrescriber tool. Medica... worry about whether they are,getting the most out...er,the brainchild of MIT Professor Glen Urban, pro...seniors quickly find their best Medicare insurance...
...erations, NAPLES, Fla., Sept. 8 Algenol Biofuels...vanced third generation biofuels,technology, today...as Chief,Science Officer. Dr. Coleman, currently t... the University of Toronto, has over 20 years of,e...iochemistry of,photosynthetic carbon metabolism in...
Other Biology Technology:Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc. 2On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2Algenol Biofuels Appoints Chief Science Officer 2
(Date:11/25/2009)...the California Institute of Technology (Caltech) h... behavior in the fruit fly, Drosophila melanogast...the relationship between the neurotransmitter dopa...(ADHD), are described in the December issue of the...ains only about 20,000 neurons and has long been c...
(Date:11/25/2009)...ve easy lives. In addition to mammalian immune sys...ies called bacteriophages, viruses that kill half ...bacteria and another class of microorganisms calle...s such as deep-sea volcanic vents) manage just fin... defense system that helps protect them from many ...
(Date:11/25/2009)...he Cell Death Research Laboratory in the Universit...ed the prestigious Johnson & Johnson Focused Fundi...rain cell damage in Parkinson,s disease. The award...ort of innovation and excellence in science, was a... this month at an event at the Hyatt Regency Hotel...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2American Oriental Bioengineering Announces Change in Independent Auditor 13494 1For Macho Men Doctor Visits Are Less Likely 54168 1For Macho Men Doctor Visits Are Less Likely 54168 2Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 1Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 2Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 3Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 4Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 5Vion Pharmaceuticals Reports 2009 Second Quarter And Six Month Results 54163 6
...is release is also available in French . , Mon...ied what may be a pivotal first step towards the r...njury, using the bodys own stem cells. , This s...of the National Academy of Science, identifies key...critical information that could lead to novel ther...
...entists at John Carroll University, working in its... affordable accessory that appears to reduce the s...n shown to improve sleep patterns among people who... researchers have created glasses designed to bloc...an rhythm, which leads to improvement in ADHD symp...
...kville, Md., November 12, 2007 On September 10, 2...t several multivitamin supplements did not contain...s, B-50 Tablets, manufactured by IVC, Industries, ... Supplement Verification Program and carries the U...tudied the verified product to confirm the announc...
Other Biology News:Researchers take first steps towards spinal cord reconstruction following injury 2Market testing of dietary supplements and drugs underscores value of USP's public health programs 2
GeneAmp PCR System 2700 from Applied Biosystems
...low Perm/Wash Buffer I can be used in intracellula...ing proteins to permeabilize cells and to serve as... saponin-mediated cell permeabilization is a rever...n the presence of saponin during intracellular sta...
Mouse Anti-PPP4C Polyclonal Antibody, Unconjugated from Abnova Corporation
...endly Eppendorf Thermomixer R offers maximum appli...quire shaking, heating, and cooling. Its active he...plication and temperature control ranges. Five dif... micro test tubes, are available for: 0.5 ml, 1.5 ...
Biology Products: